palmidrol has been researched along with Neurodegenerative Diseases in 10 studies
palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection
palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.
Neurodegenerative Diseases: Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Here, we aim to investigate the effects of palmitoylethanolamide (PEA) combined with luteoline (PEA-LUT), an endocannabinoid with anti-inflammatory and neuroprotective effects, on behavior, cognition, and cortical activity in a sample of FTD patients." | 5.56 | Effects of Palmitoylethanolamide Combined with Luteoline on Frontal Lobe Functions, High Frequency Oscillations, and GABAergic Transmission in Patients with Frontotemporal Dementia. ( Assogna, M; Bonnì, S; Borghi, I; Caltagirone, C; Casula, EP; D'Acunto, A; Di Lorenzo, F; Koch, G; Martorana, A; Minei, M; Motta, C; Porrazzini, F; Samà, D, 2020) |
| " The properties of PEA, especially of its micronized or ultra-micronized forms maximizing bioavailability and efficacy, have sparked a series of innovative research to evaluate its possible application as therapeutic agent for neurodegenerative diseases." | 2.82 | Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to Humans. ( Caltagirone, C; Cutuli, D; Landolfo, E; Petrosini, L, 2022) |
| "Here, we aim to investigate the effects of palmitoylethanolamide (PEA) combined with luteoline (PEA-LUT), an endocannabinoid with anti-inflammatory and neuroprotective effects, on behavior, cognition, and cortical activity in a sample of FTD patients." | 1.56 | Effects of Palmitoylethanolamide Combined with Luteoline on Frontal Lobe Functions, High Frequency Oscillations, and GABAergic Transmission in Patients with Frontotemporal Dementia. ( Assogna, M; Bonnì, S; Borghi, I; Caltagirone, C; Casula, EP; D'Acunto, A; Di Lorenzo, F; Koch, G; Martorana, A; Minei, M; Motta, C; Porrazzini, F; Samà, D, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Landolfo, E | 1 |
| Cutuli, D | 1 |
| Petrosini, L | 1 |
| Caltagirone, C | 2 |
| Assogna, M | 2 |
| Di Lorenzo, F | 2 |
| Martorana, A | 2 |
| Koch, G | 2 |
| Casula, EP | 1 |
| Borghi, I | 1 |
| Bonnì, S | 1 |
| Samà, D | 1 |
| Motta, C | 1 |
| D'Acunto, A | 1 |
| Porrazzini, F | 1 |
| Minei, M | 1 |
| Petrosino, S | 2 |
| Schiano Moriello, A | 1 |
| Davis, MP | 1 |
| Behm, B | 1 |
| Mehta, Z | 1 |
| Fernandez, C | 1 |
| Fidaleo, M | 1 |
| Fanelli, F | 1 |
| Ceru, MP | 1 |
| Moreno, S | 1 |
| Mattace Raso, G | 1 |
| Russo, R | 1 |
| Calignano, A | 1 |
| Meli, R | 1 |
| Di Marzo, V | 1 |
| Skaper, SD | 1 |
| Facci, L | 1 |
| Scuderi, C | 1 |
| Steardo, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Palmitoylethanolamide on Reducing Opioid Consumption for Postoperative Pain and Inflammation Following Below Knee Fracture Fixation: A Pilot Study.[NCT05317676] | Phase 2 | 0 participants (Actual) | Interventional | 2023-05-31 | Withdrawn (stopped due to Sponsor suspending temporarily.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for palmidrol and Neurodegenerative Diseases
| Article | Year |
|---|---|
Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to Humans.
Topics: Amides; Animals; Ethanolamines; Humans; Neurodegenerative Diseases; Palmitic Acids; Rodentia | 2022 |
Synaptic Effects of Palmitoylethanolamide in Neurodegenerative Disorders.
Topics: Alzheimer Disease; Amides; Animals; Ethanolamines; Neurodegenerative Diseases; Palmitic Acids | 2022 |
Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries-A Systematic Review.
Topics: Alzheimer Disease; Amides; Amyotrophic Lateral Sclerosis; Animals; Autism Spectrum Disorder; Endocan | 2020 |
The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review.
Topics: Amides; Animals; Ethanolamines; Humans; Mental Disorders; Neurodegenerative Diseases; Pain; Palmitic | 2019 |
Neuroprotective properties of peroxisome proliferator-activated receptor alpha (PPARα) and its lipid ligands.
Topics: Amides; Animals; Endocannabinoids; Ethanolamines; Humans; Ligands; Mental Disorders; Neurodegenerati | 2014 |
Palmitoylethanolamide in CNS health and disease.
Topics: Amides; Animals; Anti-Inflammatory Agents; Central Nervous System; Ethanolamines; Humans; Inflammati | 2014 |
The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.
Topics: Amides; Analgesics; Animals; Anti-Inflammatory Agents; Chemistry, Pharmaceutical; Dietary Supplement | 2017 |
Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide.
Topics: Amides; Animals; Cell Communication; Central Nervous System; Endocannabinoids; Ethanolamines; Humans | 2012 |
2 other studies available for palmidrol and Neurodegenerative Diseases
| Article | Year |
|---|---|
Effects of Palmitoylethanolamide Combined with Luteoline on Frontal Lobe Functions, High Frequency Oscillations, and GABAergic Transmission in Patients with Frontotemporal Dementia.
Topics: Activities of Daily Living; Aged; Amides; Cognition; Ethanolamines; Evoked Potentials, Motor; Female | 2020 |
Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer's disease.
Topics: Alzheimer Disease; Amides; Animals; Cell Survival; Cells, Cultured; Disease Models, Animal; Endocann | 2013 |